Equity Components [Axis]
Common Stock [Member]
Title of Individual [Axis]
Harel Gadot [Member]
Board of Directors [Member]
Award Type [Axis]
NIS [Member]
Exercise Price Range [Axis]
Exercise Price One [Member]
Exercise Price Two [Member]
Purchaser [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
Securities Purchase Agreement [Member]
Investors [Member]
Range [Axis]
Maximum [Member]
Minimum [Member]
Hezi Himelfarb [Member]
Exercise Price Three [Member]
Legal Entity [Axis]
Microbot Israel [Member]
Income Statement Location [Axis]
General and Administrative Expense [Member]
Employees [Member]
Employees and Consultant [Member]
Exercise Price Four [Member]
Exercise Price Five [Member]
CardioSert Ltd [Member]
Directors [Member]
Class of Stock [Axis]
Series A Convertible Preferred Stock [Member]
Research and Development Expense [Member]
Before Reverse Split [Member]
Exercise Price Six [Member]
Contract Research Agreements [Member]
Second Phase [Member]
Pre-Funded Warrant [Member]
Exercise Price Seven [Member]
Series A (2013) [Member]
Series A (2015) [Member]
Series B (2016) [Member]
Board of Directors [Member]
Investment Type [Axis]
US Treasury Bond [Member]
Phase 2.1 [Member]
Alliance Investment Management, Ltd. [Member]
NIS [Member]
Non-Executive Officer [Member]
Related Party [Axis]
Technion Research and Development Foundation Limited [Member]
Exercise Price Eight [Member]
Balance Sheet Location [Axis]
Derivative Warrant Liability [Member]
Adjustments for New Accounting Pronouncements [Axis]
Accounting Standards Update 2017-11 [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Series A Preferred Shares [Member]
Series A Preferred Stock [Member]
Additional Paid-in Capital [Member]
Treasury Shares [Member]
Accumulated Deficit [Member]
Temporary Equity [Member]
Property, Plant and Equipment, Type [Axis]
Research Equipment and Software [Member]
Furniture and Office Equipment [Member]
Leasehold Improvements [Member]
Interested and Related Parties [Member]
Income Tax Authority, Name [Axis]
US Tax Authority [Member]
Israel Tax Authority [Member]
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Israeli Innovation Authority [Member]
2013 Through December 31, 2019 [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Joseph Mona [Member]
Exercise Price Nine [Member]
Underwriter [Member]
Warrant One [Member]
Warrant Two [Member]
Warrant to Underwriters 1.2019 [Member]
Warrant to Underwriters 1.2019 One [Member]
Warrant to Underwriters 1.2019 Two [Member]
Warrant to Underwriters 12.2019 [Member]
Warrant to Underwriters 12.2019 One [Member]
Warrant to Underwriters 12.2019 Two [Member]
Plan Name [Axis]
Share Incentive Plan [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business Flag
Entity Emerging Growth Company
Entity Shell Company
Entity Public Float
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash and cash equivalents
Short term marketable security
Restricted cash
Prepaid expenses and other assets
Total current assets.
Property and equipment, net
Operating right-of-use assets
Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payables
Provision for extinguishment dispute
Lease liabilities
Accrued liabilities
Total current liabilities
Non current liabilities:
Long-term lease liabilities
Total liabilities
Commitments and contingencies
Stockholders' equity:
Common stock; $0.01 par value; 60,000,000 and 200,000,000 shares authorized as of December 31, 2019 and December 31, 2018 7,185,628 and 3,012,343 shares issued and outstanding as of December 31, 2019 and December 31, 2018
Additional paid-in capital
Treasury shares
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Research and development
General and administrative
Operating loss
Financing expenses, net
Capital Gain
Net loss
Basic and diluted net loss per share
Basic and diluted weighted average common shares outstanding (see note 1.D)
Statement of Comprehensive Income [Abstract]
Net loss
Other comprehensive (loss) /(income):
Net unrealized (loss) / income on available for sale securities
Comprehensive loss
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Share-based compensation
Exercise of options
Exercise of options, shares
Common shares classified out of temporary equity
Common shares classified out of temporary equity, shares
Rescission of share purchase agreement
Shares issued as consideration-vendors
Shares issued as consideration-vendors, shares
Conversion of preferred A shares to common stock
Conversion of preferred A shares to common stock, shares
Issuance of common stock and warrants net of issuance costs
Issuance of common stock and warrants net of issuance costs, shares
Cashless exercise of warrants, shares
Unrealized loss on marketable debt security
Balance
Balance, shares
Statement of Stockholders' Equity [Abstract]
Temporary equity
Statement of Cash Flows [Abstract]
Operating activities:
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization
Capital gain from sales of property and equipment
Share-based compensation expense
Shares issued to a vendor
Non cash and accrued interest
Changes in assets and liabilities:
Prepaid expenses and other assets
Account payables and other accrued liabilities
Net cash flows used in operating activities
Investing activities:
Purchase of property and equipment
Sales of property and equipment
Purchase of marketable debt securities
Net cash flows used in investing activities
Financing activities:
Deferred financing fees
Issuance of common stock and warrants, net of issuance costs
Net cash flows provided by (used in) financing activities
Increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at ending of period
Non-cash activities:
Right-of-use assets obtained in exchange for new operating lease obligations
Supplemental disclosure of cash flow information:
Cash received from interest
Rescission of share purchase agreement
Conversion of Series A Convertible Preferred Stock into common stock
Financing fees included in other receivable
Temporary equity classified to permanent equity
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Short-term Investments [Abstract]
Marketable Security
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets
Leases [Abstract]
Leases
Property, Plant and Equipment [Abstract]
Fixed Assets, Net
Payables and Accruals [Abstract]
Accrued Liabilities
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Equity [Abstract]
Share Capital
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Share
Research and Development [Abstract]
Research and Development Expenses, Net
General and Administrative Expense [Abstract]
General and Administrative Expenses
Related Party Transactions [Abstract]
Transactions and Balances With Related Parties
Income Tax Disclosure [Abstract]
Taxes on Income
Subsequent Events [Abstract]
Subsequent Events
Basis of Presentation
Financial Statement in U.S. Dollars
Cash and Cash Equivalents
Restricted Cash
Fair Value of Financial Instruments
Fixed Assets
Liabilities Due to Termination of Employment Agreements
Basic and Diluted Net Loss Per Share
Research and Development Expenses, Net
Share-Based Compensation
Reclassifications
Income Taxes
Short-Term Investments
Leases
Warrants
Recently Issued Accounting Pronouncements
Estimated Useful Lives of Property and Equipment
Schedule of Cumulative Effect of Adoption of ASU 2017-11
Schedule of Marketable Debt Securities
Schedule of Other Current Assets
Schedule of Supplemental Cash Flow Information Related to Operating Leases
Schedule of Maturities of Lease Liabilities
Schedule of Supplemental Information Related to Leases
Summary of Fixed Assets, Net
Summary of Accrued Liabilities
Summary of Stock Option Activity
Schedule of Stock Options Outstanding
Schedule of Stock Options Valuation Assumptions
Schedule of Warrants Outstanding
Schedule of Basic and Diluted Net Loss Per Share
Schedule of Research and Development Expenses
Schedule of General and Administrative Expenses
Schedule of Related Party Transaction and Balances
Schedule of Deferred Tax Assets
Schedule of Statutory Corporate Tax Rate and Effective Income Tax Rate
Cash and cash equivalent
Reverse stock split
Reverse stock split, shares
Statistical Measurement [Axis]
Property, plant and equipment, useful life
Cumulative effect adjustment
Cost
Accrued interest
Fair value
Amounts due from government institutions
Deferred costs related to issuance of common shares (see Note 16)
Prepaid expenses and others
Total Other current assets
Short-term lease term
Lease liabilities for operating leases
Cash payments for operating leases
2020
2021
2022
2023
2024
2025
Total future lease payments
Less imputed interest
Total lease liability balance
Operating lease right of use asset
Operating lease - current
Operating lease - non-current
Total Operating lease liability
Operating leases weighted average remaining lease term (in years)
Operating leases weighted average discount rate
Cost
Accumulated Depreciation
Net book value
Employee-related liabilities
Amounts due to certain government institution
Other current liabilities
Total Accrued Liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Total grants obtained
Royalties payable as percentage of future sales
Contract expected costs
Settlement amount
Number of post-stock split shares returned
Purchase price of plaintiffs
Beneficial ownership percentage
Litigation settlement
Initial payment
Number of common shares acquired
Number of common shares acquired, value
Investments
Buy back amount per patent
Monthly consultation fee
Monthly consultation fee in USD
Currency exchange rate, description
Authorized capital stock
Rights to acquire shares of common stock
Designated preferred stock
Number of common stock shares sold during the period
Common stock price per share
Proceeds from issuance of shares
Placement agent fee and expenses
Warrant to purchase for common stock
Warrant price per share
Warrants value
Proceeds from issuance and sale of stock
Warrants term
Proceeds from issuance of warrants
Number of stock options granted
Number of stock option granted as adjusted to reflect merger
Weighted-average exercise price per share, granted
Stock option merger retroactively adjusted exercise price per share
Ordinary shares, par value
Stock option vested term
Stock-based employee compensation
Number of option exercised
Aggregate intrinsic value of outstanding options
Aggregate intrinsic value of exercisable options
Unrecognized compensation costs, net of expected forfeitures
Unrecognized compensation weighted average period
Acquisition price of assets
Warrant outstanding
Shares of common stock
Number of stock options outstanding, Outstanding at beginning of period
Number of stock options outstanding, Granted
Number of stock options outstanding, Cancelled
Number of stock options outstanding, Forfeited
Number of stock options outstanding, Outstanding at end of period
Number of stock options outstanding, Vested at end of period
Weighted average exercise price, Outstanding at beginning of period
Weighted average exercise price, Granted
Weighted average exercise price, Forfeited
Weighted average exercise price, Cancelled
Weighted average exercise price, Outstanding at end of period
Weighted average exercise price, Vested at end of period
Exercise price
Stock options outstanding
Weighted average remaining contractual life
Stock options exercisable
Expected volatility, minimum
Expected volatility, maximum
Expected volatility
Risk-free interest, minimum
Risk-free interest, maximum
Risk-free interest
Dividend yield
Expected life of up to (years)
Number of outstanding warrants
Exercise price
Number of exercisable warrants
Exercisable Through
Net loss attributable to shareholders of the Company
Net loss attributable to shareholders of preferred shares
Net loss used in the calculation of basic net loss per share
Net loss per share
Weighted average number of common shares
Payroll and related expenses
Share-based compensation
Materials
Patents
Office and maintenance expenses
Rent R&D
Professional services
Depreciation
Other
Less: Grants received from IIA & EC
Research and development expense
Travel
Marketing expenses
Public and investor relations
Insurance
Government fees
Other
General and administrative expenses
Directors fees and insurance
Total
Other accounts payable
Tax Period [Axis]
Corporate income tax rate
Net operating losses carried forward
Operating loss carryforwards, expiration
Net operating loss carry-forward
Total deferred tax assets
Valuation allowance
Net deferred tax assets
Net loss as reported in the statements of operations
Statutory tax rate
Income Tax under statutory tax rate
Change in valuation allowance
Actual income tax
Annual base salary
Bonus percentage
One-time special bonus percentage
Non qualified option to purchase common stock
Exercise price per share
Stock non option vesting description
Before Reverse Split [Member]
Board of Directors [Member]
CardioSert Ltd [Member]
Contract Research Agreements [Member]
Directors [Member]
Employees and Consultant [Member]
Employees [Member]
Exercise Price Five [Member]
Exercise Price Four [Member]
Exercise Price One [Member]
Exercise Price Six [Member]
Exercise Price Three [Member]
Exercise Price Two [Member]
Hazel Gadot [Member]
Hezi Himelfarb [Member]
Israeli Innovation Authority [Member]
Microbot Israel [Member]
Pre-Funded Warrant [Member]
Purchaser [Member].
Second Phase [Member]
Securities Purchase Agreement [Member]
Series A Convertible Preferred Shares [Member]
Warrants [Policy Text Block]
Schedule of supplemental cash flow information related to operating Leases [Table Text Block]
Exercise Price Seven [Member]
Series A (2013) [Member]
Series A (2015) [Member]
Series B (2016) [Member]
Board of Directors [Member]
Bonding Agent [Member]
Schedule of Cumulative Effect of Adoption [Table Text Block]
Derivative Warrant Liability [Member]
Accumulated Deficit [Member]
Technion Research And Development Foundation Limited [Member]
2013 Through June 30, 2019 [Member]
NIS [Member]
Phase 2.1 [Member]
Alliance Investment Management, Ltd. [Member]
Non Executive Officer [Member]
Provision for extinguishment dispute.
Schedule of Supplemental Information Related to Leases.
Marketable securities amortized cost.
Marketable securities fair value.
2013 Through September 30, 2019 [Member]
Net Sales Royalty Percentage
Contract expected costs.
Buy back amount per patent.
Rights to acquire shares of common stock.
Placement agent fee and expenses.
Number of stock option granted as adjusted to reflect merger.
Stock option merger retroactively adjusted exercise price per share.
Acquisition price of assets.
Exercise Price Eight [Member]
Class of warrant or righst month year from which warrants or rights exercisable.
Non-management Directors [Member]
Option Agreements [Member]
Temporary Equity [Member]
Rescission of share purchase agreement.
Conversion of convertible notes into preferred A shares.
Temporary equity classified to permanent equity.
General and administrative expenses [Text Block].
Schedule of Property and Equipment Useful Lives [Table Text Block]
Schedule of General and Administrative Expense [Table Text Block]
Research Equipment and Software [Member]
Furniture And Office Equipment [Member]
Amounts due to certain government institution.
Alpha Capital [Member]
Series A (2011) [Member]
Series A (2013) [Member]
Series A (2013) One [Member]
Series A (2015) [Member]
Series A (2016) [Member]
Series B (2016) [Member]
Interested and Related Parties [Member]
2016 [Member]
2017 [Member]
From 2018 [Member]
US Tax Authority [Member]
Tax Act [Member]
From January 1, 2018 [Member]
Capital gain/(loss).
Common shares classified out of temporary equity.
Common shares classified out of temporary equity, shares.
Cashless exercise of warrants, shares.
Financing fees included in other receivable.
First Quarter of 2019 [Member]
Fourth Quarter of 2019 [Member]
2013 Through December 31, 2019 [Member]
Joseph Mona [Member]
Exercise Price Nine [Member]
Underwriter [Member]
Warrant One [Member]
Warrant Two [Member]
Warrant to Underwriters 1.2019 [Member]
Warrant to Underwriters 1.2019 One [Member]
Warrant to Underwriters 1.2019 Two [Member]
Warrant to Underwriters 12.2019 [Member]
Warrant to Underwriters 12.2019 One [Member]
Warrant to Underwriters 12.2019 Two [Member]
Office and maintenance expenses.
Revenues from grants.
Amount of general and administrative expense related to public and investor relation.
The amount of expense provided in the period for government service fees.
Operating Loss Carryforwards, Expiration.
One-time special bonus percentage.
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non options.
Stock non option vesting description.
Cumulative effect adjustment.
Number of stock options outstanding, cancelled.
Weighted average exercise price, cancelled.
Bonus percentage.
Number of post-stock split shares returned.
Non cash and accrued interest.
Right-of-use assets obtained in exchange for new operating lease obligations.
Marketable securities accrued interest
Share Incentive Plan [Member]
Monthly consultation fee in USD.
Currency exchange rate, description.
BoardofDirectorMember
Israel, New Shekels
Retained Earnings [Member]
Assets, Current
Assets
Liabilities, Current
Liabilities
Treasury Stock, Value
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Operating Income (Loss)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Shares, Outstanding
Conversion of Stock, Amount Converted
Gain (Loss) on Disposition of Property Plant Equipment
Increase (Decrease) in Prepaid Expense and Other Assets
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Property, Plant, and Equipment
Payments to Acquire Marketable Securities
Net Cash Provided by (Used in) Investing Activities
Payments of Financing Costs
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Earnings Per Share, Policy [Policy Text Block]
Research and Development Expense, Policy [Policy Text Block]
Lessee, Leases [Policy Text Block]
Other Assets, Current
Lessee, Operating Lease, Liability, Payments, Due
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Property, Plant and Equipment, Gross
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
RevenuesFromGrants
Other General and Administrative Expense
Costs and Expenses, Related Party
Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Net of Valuation Allowance